RAPP en las noticias
Precisión, empatía, activación del crecimiento
Tamtam encontró 20 artículos recientes sobre RAPP.
- Analysts Conflicted on These NA Names: General Dynamics (GD), Rapport Therapeutics, Inc. (RAPP) and First Solar (FSLR)
- Market Movers | Winners: QNC, EGHT, FSLY | Losers: CGEM, ALKT, RAPP
- Rapport Therapeutics (RAPP) officer flags $553K stock sale plan
- Rapport Therapeutics (NASDAQ:RAPP) Reaches New 12-Month High - Should You Buy?
- Rapport Therapeutics (RAPP) CEO Abraham Ceesay sells 51,499 shares via 10b5-1 plan
- Omnicom moves Rapp into Critical Mass and global CEO exits in restructure
- RAPP: RAP-219 shows strong efficacy in epilepsy, with phase III and LAI programs advancing
- Third Rock sells shares of RAPP (NASDAQ: RAPP) under Form 144
- (RAPP) Volatility Zones as Tactical Triggers
- Form 144 shows proposed 500-share sale; insider 10b5-1 trades (RAPP)
- Form 144: Morgan Stanley Smith Barney (NASDAQ: RAPP) lists 360-share sale
- Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Consensus Rating of "Moderate Buy" by Analysts
- Is Rapport Therapeutics (RAPP) Turning Its TARPγ8 Precision Seizure Program Into a Scalable Platform?
- (RAPP) Risk Channels and Responsive Allocation
- How Rapport’s Greater China RAP-219 Licensing Deal At Rapport Therapeutics (RAPP) Has Changed Its Investment Story
- Rapp at Home receives grant to reduce risk of social isolation
- Marketing Skills Trust, Ogilvy and Rapp to run mentorships in memory of ex-Ogilvy chief
- New Analyst Forecast: $RAPP Given $47 Price Target
- Could RAP-219’s Upcoming Data Reveal a Turning Point for Rapport Therapeutics’ Pipeline Strategy (RAPP)?
- New Analyst Forecast: $RAPP Given $47.0 Price Target
Artículos recopilados por Tamtam y conservados cuando tratan sobre la empresa, del más reciente al más antiguo. Cada uno enlaza con su fuente.
¿Vendes a empresas como RAPP?
Tamtam encuentra las empresas que encajan con tu cliente ideal, investiga cada cuenta y te dice a quién contactar y cuándo.
Encontrar empresas similares